Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate.

For all PSM analyses, marginal significance at the type I error level of 0.05 was used.

also in 5,069 other papers

These observations are consistent with those from another network meta-analysis comparing the relative efficacy of peginterferon beta-1a versus other injectable first-line DMTs, including GA, which showed a numerical trend favoring peginterferon beta-1a 125 mcg Q2W versus GA 20 mg/ml QD for 12- and 24-week CDW but not for ARR. 25 Two recent network meta-analyses also demonstrated no difference in efficacy between peginterferon beta-1a and either regimen of GA on ARR, 26 , 27 though a positive impact on risk of diseas

also in 1,012 other papers